Metastatic Prostate Cancer?
Myriad myRisk® Improves Your Outcome
If you or a loved one has been diagnosed with metastatic prostate cancer, there are now advanced therapies for men with metastatic prostate cancer. Knowing your individual, genetic mutation status is THE ONLY WAY to determine if you qualify for these new treatments. The Myriad myRisk test was designed to quickly and accurately provide you and your physician with personalized genetic results, so they can confidently personalize your treatment plan.
Germline testing has broad insurance coverage, including Medicare, and most patients pay $0
National cancer guidelines recommend germline testing for men with metastatic prostate cancer
The option to test directly from home is available
Advanced Cancer Treatments
Up to 1 in 6 men with prostate cancer have a genetic mutation that may have caused their cancer¹. Cancer cells with germline HRR mutations, like BRCA1, BRCA2, or ATM are more susceptible to treatments that directly or indirectly damage DNA. If you carry a BRCA mutation, your cancer cells are more likely to respond to newer treatments like PARP inhibitor therapy.
What is BRCA?
Both men and women have BRCA genes. Normally, the proteins produced by the BRCA1 and BRCA2 genes prevent cells from developing into cancer. When one of these genes has a mutation, the cell has a hard time preventing tumors from growing. This can cause an increased risk for cancer.
With a simple blood or saliva test, Myriad can let you and your physician know if you have a genetic mutation causing your cancer, and if you may be a candidate for advanced cancer therapies.
Blood or saliva sample is collected
Sample is sent directly to Myriad
Your physician will receive your confidential results and inform you if you are eligible for advanced cancer therapies
Submit the form below to receive your METS Patient Guide
Confirming your genetic mutation status is the only way to determine if new PARP inhibitor therapy may be appropriate for you. The Myriad myRisk® hereditary cancer test was designed to quickly provide accurate results, so they can confidently personalize your treatment plan.
*If for some reason you do not receive the email with your Patient Guide download, please check your junk folder.
- Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines Nicolosi et al. JAMA Oncol 2019